Compare Citius Pharmaceuticals Inc (CTXR) vs Walmart Stores Inc (WMT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs Walmart Stores Inc — how do they compare? Citius Pharmaceuticals Inc trades at $0.73 (market cap $18.73M), while Walmart Stores Inc trades at $113.04 (market cap $896.56B). The key difference: Walmart Stores Inc is far larger — about 47867.6× Citius Pharmaceuticals Inc's market cap, and Walmart Stores Inc pays a 0.88% dividend while Citius Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| CTXR | WMT | |
|---|---|---|
Market Cap | $18.73M | $896.56B |
Sector | Health | Consumer Staples |
52-Week High | $1.82 | $134.20 |
52-Week Low | $0.48 | $96.05 |
Enterprise Value | $14.95M | $960.01B |
Volume | — | 5,675,288 |
Dividend Yield | — | 0.88% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR is trading at $0.68, up 6.28% today, with a bullish technical signal from moving averages. The company shows strong commercial momentum with LYMPHIR cancer treatment revenue reaching $5.6 million in H1 2026, though it remains unprofitable with a -823% net margin. Analyst consensus is strongly bullish with 83% buy ratings.
The outlook depends on LYMPHIR's commercial success offsetting deep losses. Near-term catalysts include expanded market access and combination therapy data, but high cash burn and execution risks require monitoring. The stock offers speculative growth potential in oncology but carries significant financial risk.
Walmart (WMT) stock trades at $113.26, up 1.26% today, with a neutral technical signal and strong analyst consensus. The company demonstrates robust fundamentals with revenue growth to $681.0B in 2025 and net income of $19.4B, alongside consistent earnings beats. Recent news highlights operational innovations like drone delivery expansion and AI tools, while maintaining a solid dividend.
Outlook remains positive with a $142 consensus price target, though risks include competitive pressures and margin sustainability. The stock presents a long-term opportunity given its defensive positioning and growth initiatives, but investors should monitor execution against Amazon and consumer spending trends.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About Walmart Stores Inc
Walmart Inc. operates discount stores, supercenters, and neighborhood markets. The Company offers merchandise such as apparel, house wares, small appliances, electronics, musical instruments, books, home improvement, shoes, jewelry, toddler, games, household essentials, pets, pharmaceutical products, party supplies, and automotive tools. Walmart serves customers worldwide.
Read more on WMT →
